



Age-related macular degeneration (AMD) is a complex, degenerative and progressive disease involving the multiple genetic and environmental fac-
tors that can result in severe visual loss. The etiology of AMD is not well understood. Many theories exist and feature mechanisms of oxidative stress, 
atherosclerotic-like changes, genetic predisposition and infl ammation. The most recent clinical studies appointed to a great role of infl ammation and 
C-reactive protein (CRP) in the pathogenesis of AMD. There is a large body of evidence indicating the association of CRP with endothelial dysfunction, 
oxidative stress and production of reactive oxygen species (ROS), as well as with lipid status disorder in AMD patients. According to recent studies, 
CRP is defi nitely not only the infl ammatory marker but also a mediator of development of the vascular disorders in the retinal circulation. The results 
obtained from the present studies may help our understanding the pathogenesis of the retinal vascular disease associated with high levels of CRP.
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Age-related macular degeneration (AMD) is the 
most common cause of visual impairment in the 
individuals over 50 years of age, with the preva-
lence of 0.05% before the age of 50 rising to 30% 
after 74 years of age. It is a complex, degenerative 
and progressive disease involving the multiple ge-
netic and environmental factors that can result in 
severe visual loss. The molecular mechanisms 
causing the AMD remain unknown, although in-
fl ammatory processes have been implicated by 
identifi cation of the AMD susceptibility genes en-
coding complement factors (1) and the presence 
of the complement proteins in drusen (2).
One of the pathological hallmarks of AMD is the 
focal deposition of the extracellular material be-
tween the retinal pigmented epithelium (RPE) and 
Bruch’s membrane called drusen. Drusen are visu-
alised as yellow deposits under the retinal pigment 
epithelium and neurosensory retina and are asso-
ciated with atrophy and depigmentation of the 
overlying retinal pigment epithelium. Although a 
few small (< 65 μm) hard drusen can be found in at 
least 96% of aged population, the presence of a 
numerous larger (> 125 μm) hard drusen, and es-
pecially large, soft drusen (125-250 μm) in the mac-
ula is considered particularly when accompanied 
by pigment irregularities or depigmentation a ma-
jor risk factor for developing the advanced form of 
AMD (3). The material, referred to as drusen is com-
posed of several cellular and humoural constitu-
ents of systemic infl ammatory and immune medi-
ated processes such as HLA-DR, immunoglobulin 
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λ and κ light chains, complement components 5 
and 9, amyloid A, amyloid P component, fi brino-
gen, vitronectin and C-reactive protein (4). Moreo-
ver, the accumulation of drusen can damage the 
surrounding structures, inculding Bruch’s mem-
brane, and is associated with visual defi cit that 
precede the loss of visual accuity in AMD (5).
The aetiology of AMD is not well understood. 
Many theories exist and feature mechanisms of 
oxidative stress, atherosclerotic-like changes, ge-
netic predisposition and infl ammation (6).
Risk factors for AMD
Several risk factors have been postulated to take 
an important role in development of AMD. Age is 
the strongest risk factor for AMD. The prevalence 
of AMD increases with age in white individuals (7). 
Female gender may be a risk factor in individuals 
aged over 75 years with the relative risk for neo-
vascular form of AMD as much as twice that ob-
served in age-matched men (8).
AMD is more common in white individuals than in 
people of other ethnic origin (9). It is postulated 
that increased levels of melanin could increase the 
free-radical scavenging potential of the RPE and 
Bruch’s membrane, thereby protecting against the 
risk of AMD (10). Several studies have found an as-
sociation between advanced AMD and comple-
ment factor H, an integral component of the alter-
native pathway of complement activation (11). 
Other factors such as factor B and complement 
components C2 and C3 are also associated with 
AMD (12). A few clinical trials showed a relationship 
between the development of exudative lesions 
and a history of current cigarette smoking. Smok-
ing increases the risk of the exudative type of AMD 
2.8 times for females and 3.2 times for current 
smokers in men. Smoking cessation lowers the rel-
ative risk of AMD (13). Some studies have shown a 
direct association between age-related macular 
degeneration and raised concentration of choles-
terol both in the serum (14) and in the diet (15). In-
creased concentration of HDL-cholesterol is con-
sidered to be cardioprotective have been shown 
to be associated with a reduced risk of AMD (16).
Several studies have described the benefi cial ef-
fects of dietary carotenoids in slowing the course 
of the disease. A multicentre randomized trial has 
shown that oral supplementation with high levels 
of antioxidants and minerals are eff ective in slow-
ing the progression of advanced stages of AMD 
(17). Some case-control studies have found evi-
dence of decreasing risk of neovascular AMD 
among individuals reporting the highest intake of 
omega-3 fatty acids and fi sh (18). The use of exog-
enous supplements of oestrogen in post-meno-
pausal women was associated with a lower risk of 
AMD in a study performed by the Eye Case Control 
Study Group (17).
It has been postulated that light plays a role in the 
development of AMD. It has been hypothesized 
that the photosensitization reactions may be in-
volved in the development of AMD, via synthesis 
of the reactive oxygen species such as: superoxide, 
hydrogen peroxide, and singlet oxygen, which 
may damage the RPE and Bruch’s membrane (19). 
Blue iris color has been inconsistently implicated 
as a risk factor for AMD (20). Results from Beaver 
Dam Study suggest that people who spent leisure 
time outdoors were at increased risk of develop-
ing early AMD (21).
Chronic conditions and diseases such as athero-
sclerosis (22), diabetes (23) and cardiovascular dis-
eases (24) as well are known as risk factors for 
AMD.
The pathological features of AMD
The pathology of age-related macular degenera-
tion is characterized by degenerative changes in-
volving the outer portion of the retina, retinal pig-
ment epithelium, Bruch’s membrane, and less 
prominently the choriocapillaris. AMD may be clas-
sifi ed into three forms: early, intermediate, and ad-
vanced. The early and intermediate forms account 
for 90% of all cases. In contrast, the advanced form 
accounts for 88% of all cases of blindness attribut-
able to AMD. The earliest signs of AMD are discrete 
yellow deposits in the deep layers of the macula, 
known as drusen. Furthermore, areas of pigmen-
tary disturbance may be observed in the underly-
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ing retinal pigment epithelium of the macula. Vis-
ual loss associated with these changes may be 
gradual, resulting from atrophy of the retinal pig-
ment epithelium and the overlying photorecep-
tors. In addition, the early form of AMD may 
progress to the intermediate and advanced forms.
Although the advanced form of AMD is less com-
mon than the early and intermediate forms, the 
potential visual loss with advanced AMD is more 
signifi cant. Advanced AMD has two clinical sub-
types. Wet AMD (exudative or neovascular AMD) is 
the more common subtype and is characterized 
by proliferation of abnormal vessels in the choroid 
(a highly vascular area between the sclera and the 
retinal pigment epithelium). These choroidal neo-
vascular membranes may proliferate into the sub-
retinal space and retina and leak fl uid and blood, 
causing damage and loss of vision. Other features 
of wet AMD are detachment of the retinal pigment 
epithelium and fi brosis, often termed a disciform 
scar, which forms in the late stages of the disease 
(25).
Pathologic states such as hypoxia, ischemia, or in-
fl ammation may tip the balance of proangiogenic 
and antiangiogenic factors in favor of the forma-
tion of new blood vessels. Vascular endothelial 
growth factor (VEGF) is pivotal in ocular angiogen-
esis because it is highly selective for endothelial 
cells, hypoxia drives its synthesis, it diff uses to its 
target, and it aff ects multiple components of ang-
iogenesis such as endothelial cell proliferation, 
survival, and migration. Basic and clinical research 
implicates VEGF in the pathogenesis of choroidal 
neovascularization (CNV). Therefore, intravitreal 
drugs that block VEG have revolutionized the care 
of patients with neovascular AMD, decreasing 
growth and leakage from choroidal neovascular 
lesions and preventing moderate and severe vi-
sion loss associated with this process (26,27).
The second subtype of advanced AMD (the dry 
AMD form) involves atrophy, which progresses to 
visually signifi cant structures of the retina, such as 
the fovea, which is responsible for the sharpest 
and central visual acuity. Progressive atrophy over 
a large area is termed geographic atrophy and 
may result in severe visual loss. Geographic atro-
phy is seen as normal RPE with hypotrophy, hyper-
trophy hypo- or hyperpigmentation, atrophy, mi-
gration, loss of outer retinal cells, attenuation of 
Bruch’s membrane and choriocapillaris degenera-
tion (28).
The role of infl ammation in the 
pathogenesis of AMD
There is mounting evidence from laboratory based 
studies that infl ammation plays a key role in the 
pathogenesis of AMD (4,6,29). The infl ammatory 
marker CRP has recently been shown to be an in-
dependent risk for cardiovascular and peripheral 
arterial disease (30-32) and a pathogenic factor 
leading to endothelial dysfunction in the cell cul-
ture model (33). Moreover, elevated concentration 
of CRP has been associated with an increased risk 
for hypertension (34), and for type 1 and type 2 di-
abetes mellitus (35). Because hypertension and di-
abetes are considered major risk factors for retinal 
vascular disorders, their association with infl am-
mation and endothelial dysfunction has been sug-
gested in humans with retinopathy (36).
Atherosclerosis is a known risk factor for AMD, 
most likely through decreased choroidal blood 
fl ow, directly or indirectly impairing the function-
ing of the RPE (37,38). Atherosclerosis is also associ-
ated with elevated hsCRP concentration, which 
may contribute to the higher risk of AMD (39).
Local infl ammatory and immune-mediated events 
play a role in the development of drusen (40-42). 
Direct analysis by liquid chromatography and im-
munocytochemical analyses confi rmed that 
drusen contain proteins associated with infl amma-
tion such as fi brinogen, vitronectin, complement 
components and C-reactive protein (CRP) (43). 
Some of these proteins seem to be locally pro-
duced by damaged retinal pigment epithelium 
cells (42). Drusen components have been found in 
atheroscerotic plaques and deposits in Alzheimer 
disease (44), and AMD, atherosclerosis and Alzhe-
imer disease may partly share a similar infl amma-
tory pathogenesis.
The AMD lesion formation has been conceptual-
ized as sharing mechanisms with atheroscerotic 
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plaque formation, where LDL retention within the 
arterial wall initiates a cascade of pathologic events 
called the “response to retention hypothesis” (45). 
In atheroscelrosis Apo B100 lipoproteins become 
oxidatively modifi ed. This modifi cation stimulates 
diff erent biological processes including innate im-
mune system-mediated infl ammation which in-
duce a cascade of pathological events than culmi-
nate in atherosclerotique plaques (46). In AMD, the 
following evidence supports the “response to re-
tention” hypothesis:
Apo B100-containing lipoproteins accumulate • 
in Bruch’s membrane in the same location as 
basal deposits in drusen;
oxidatively modifi ed proteins and lipids are • 
present in Bruch’s membrane and RPE inducing 
a pathologic phenotype to RPE cells (47); and
the accumulation of infl ammatory mediators • 
whitin drusen and basal deposites indicates a 
role for the innate immune response (48).
Oxidized lipoproteins can trigger complement ac-
tivation (46). CD36 is the major receptor implicated 
in uptaking the oxidized low density lipoproteins 
and is expressed also in RPE cells. It has been sug-
gested that CD36 may have a role not only in the 
clearance of oxidized lipids from Bruch’s mem-
brane (49) but also in the subsequently inducing 
an immune response (50).
In addition to aforementioned facts, the presence 
of matrix matalloproteinases (MMPs) in higher con-
centration in the Bruch’s membrane and RPE cells, 
especially MMP-2 and MMP-9 indicate to more 
similarity between atherosclerotic plaque and 
AMD lesion formation. It is known that MMP-2 and 
MMP-9 are implicated in the degradation of extra-
cellular matrix components which can lead to 
plaque destabilization and rupture and subse-
quent future cardiovascular events, especially 
acute myocardial infarction (AMI) (51).
Chronic infl ammation seems to be a causative fac-
tor for the development of AMD. Chronic infl am-
mation results in endothelial dysfunction and fa-
cilitates the interactions between modifi ed lipo-
proteins, monocyte-derived macrophages, T-cells 
and normal cellular elements of the retinal arterial 
wall (52). Macrophages are often seen in the area 
of geographic atrophy and are apparently phago-
cytosing pigment debris, as seen by electron mi-
croscopy or immunohistochemistry methods 
(44,53). Macrophages have been documented 
both morphologically and functionally in neovas-
cular AMD (54). Activated macrophages and mi-
croglia may secrete chemokines and citokines, 
causing further cellular damage, Bruch’s mem-
brane degradation and angiogenesis (55).
The human eye is known to produce signifi cant 
quantities of 7-ketocholesterol and related sub-
stances as a direct result of photoreceptor func-
tion. In atherosclerosis oxysterols contribute to the 
conversion of macrophages into foam cells (56). 
7-ketocholesterol has recently been found to be 
localized in deposits within the choriocapilaris and 
Bruch’s membrane of aging monkies (57). Oxyster-
ols have cytotoxic and infl ammatory properties on 
RPE cells inducing reactive oxygen species genera-
tion, glutathione depletion, and reduced mito-
chondrial membrane potential infl ammation 
through activation of NFkB and eventually apop-
totic-mediated cell death in cultured RPE cells (58).
Recently, a strong association between the Y402H 
single-nucleotide polymorphism in the comple-
ment factor H (CFH) gene and AMD was found in 3 
clinic-based case control studies (59), and in a lon-
gitudinal population based study (60). Comple-
ment factor H is an essential regulator in the com-
plement system. It activates C3b and functions as 
an activation inhibitor of the alternative comple-
ment pathway (61). This single-nucleotide poly-
morphism is located in a region that contains the 
binding sites for heparin and CRP. Complement 
factor H binds to CRP, which may help inhibit the 
CRP-dependent alternative pathway activation in-
duced by damaged tissue (61). Complement factor 
H tends to prevent the assembly of complement 
complex in the arterial intima (62). It has been sug-
gested that allele-specifi c changes in activities of 
the binding sites for heparin and CRP modify the 
protective action of complement factor H (63). 
Complement-related damage to choroidal vessels 
might lead to wet AMD (11). It is possible that re-
duction of CRP levels might lower the risk of AMD. 
Some recently published papers indicated that 
CFH binds to the denaturated rather than native 
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CRP thus casting some doubt upon this link be-
tween CFH and CRP (64). It is also possible that 
persistent chronic infl ammation that is a byprod-
uct of attenuated complement-inhibitory activity 
may occur in those individuals with the risk-con-
ferring CFH SNP Y402H and that this pro-infl am-
matory state, rather than impaired binding by CFH, 
leads to CRP accumulation in AMD retina. Alterna-
tively, the role of CFH in AMD might be completely 
independent of CRP. Without a doubt, further 
studies are necessary to dissect the role, if any, of 
the CFH Y402H SNP in AMD pathogenesis. Dean-
gelis and coworkers stated that there was a clear 
genetic infl uence on AMD, and the loci 1q33 (CFH) 
and 10q26 (PLEKHA1/ARMS2/HTRA1) were the 
most strongly associated with AMD, but the varia-
tion of these genomic regions alone were unable 
to predict disease development with high accura-
cy (65). Lederman et al. demonstrated that neovas-
cular AMD was associated with altered gene ex-
pression in peripheral white blood cells that was 
not underlined by the major risk single nucleotide 
polymorphisms, and suggested that such altered 
expression may potentially serve as a biomarker 
for the disease (66). Increased levels of annexin A5 
(ANXA5) mRNA transcripts were also found in the 
WBC of patients with AMD. ANXA5 which plays a 
role in the regulation of blood clot has been found 
in atherosclerotic plaques and is proposed to have 
and anti-infl ammatory functions (67). Interestingly, 
other annexins were previously identifi ed in 
drusen (68). Recent studies have revealed pro-
found developmental consequences of mutations 
in genes encoding proteins of the lectin pathway 
of complement activation, a central component of 
the innate immune system. Apart from impair-
ment of immunity against microorganisms, it is 
known that hereditary defi ciencies of this system 
predispose one to autoimmune conditions. Poly-
morphisms in complement genes are linked to, for 
example, atypical hemolytic uremia and age-de-
pendent macular degeneration. The recently dis-
covered lectin pathway is less studied, but poly-
morphisms in the plasma pattern-recognition 
molecule mannan-binding lectin (MBL) are known 
to impact its level, and polymorphisms in the MBL-
associated serine protease-2 (MASP-2) result in de-
fects of complement activation (69).
Association of CRP with AMD
Several recent clinical studies suggest close associ-
ation between serum CRP and ocular vascular dis-
orders related to AMD. One recent study (70) dem-
onstrated a close positive association between 
CRP and cholesterol levels (especially total choles-
terol, LDL- and non-HDL cholesterol levels) in pa-
tients with AMD. AMD patients who had higher 
values of total-, LDL- and non-HDL-cholesterol val-
ues had also higher CRP values. This group of in-
vestigators succeeded to demonstrate a signifi cant 
association between incidence of AMD and CRP 
levels, especially between occurrence of AMD and 
CRP levels higher than 3 mg/L. Several recent clini-
cal studies reported that patients with the highest 
quartile of CRP (over 6.5 μg/mL) are at high risk of 
AMD (5,71). In addition, more than threefold high-
er incidence of AMD was found in women with se-
rum CRP levels exceeding 5 μg/mL (5,71). The con-
centrations of CRP used in the study of Nagaoka 
(30) (0.7 and 7 μg/mL) covered the physiological 
and pathophysiological ranges, and only high lev-
el of CRP exhibited inhibitory action in endotheli-
um-dependent vasomotor function. It appears 
that CRP levels known to predict cardiovascular 
events produce adverse eff ects on endothelial 
function in the retinal microvasculature. C-reactive 
protein (CRP) is an infl ammatory marker known to 
be associated with cardiovascular disease, and a 
link between AMD and CRP has been suggested. 
Hong et al. (72) in his systematic review summarize 
the currently available evidence from clinic-based 
and population-based studies investigating this 
association. Their meta-analysis shows that high 
serum levels (> 3 mg/L) of CRP are associated with 
a two-fold likelihood of late onset AMD, compared 
to low levels (< 1 mg/L).
De Jong et al. (73) showed, in the Rotterdam study, 
the existence of a small signifi cant association be-
tween log CRP levels and AMD incident. Kikuchi et 
al. (74) demonstrated the trends of the increased 
risk of disease with the increase of CRP, which were 
statistically signifi cant for both polypoidal choroi-
dal vasculopathy (PCV) and neovascular AMD. The 
Rotterdam study (38) found that elevated baseline 
levels of high sensitive CRP (HsCRP) were associat-
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ed with the development of early and late AMD in 
the large population-based cohort. Boey et al. (75) 
demonstrated no associations between CRP and 
AMD or cataract in general population of the Asian 
people, while higher CRP was associated with AMD 
in individuals without diabetes.
Possible mechanism for CRP 
dependent-oxidative stress and lipid 
disorder
The infl ammatory reaction is an important source 
of the oxygen-free radicals. Large amounts of su-
peroxide radicals are secreted by activated phago-
cytic leukocytes, and also formed as by-product 
during biosynthesis of leukotrienes and prostag-
landins and formation of lipid peroxides.
Proinfl ammatory cytokines play a central role in 
mediating the cellular and physiological respons-
es. Non-enzymatic oxidative modifi cation mediat-
ed by reactive oxygen species transforms low den-
sity lipoprotein (LDL) to an atherogenic molecule 
(E-LDL) that activates complement and macro-
phages and is present in the early atherosclerotic 
lesions and drusen. E-LDL accumulates in the hu-
man vascular smooth muscle cells (VSMC) where 
promotes angiotensin type 1 receptor (AT1-R) up-
regulation and stimulates VSMC migration prolif-
eration and neointimal formation while concomi-
tantly increasing reactive oxygen species (ROS) 
production. A growing body of evidence impli-
cates CRP as a direct mediator of endothelial dys-
function. CRP directly upregulates endothelial cell 
adhesion molecules: ICAM-1, VCAM-1 and E-selec-
tin, which play a key role in facilitating the leuko-
cyte-endothelial interaction. CRP also promotes 
the release of MCP-1 a key chemoatractant chem-
okine which facilitates leukocyte transmigration 
through the endothelium (11,76). Recent studies 
suggest that CRP also promotes nuclear factor 
(NF)-κB upregulation in endothelial cells (77). In 
that way CRP functions as an active participant in 
lesion formation and hence is directlly linked to 
atherosclerosis.
CRP is capable of generating the TEMPOL-sensitive 
superoxide in the endothelial layer of the retinal 
arterioles. This fi nding is consistent with recent ev-
idence showing that CRP can increase the produc-
tion of superoxide in cultured human aortic en-
dothelial cells and in porcine coronary arterioles 
(78). Clinical study of Fichtlscherer (79) reported 
that the increase of oxidative stress and the reduc-
tion of NO bioavailability were closely related to 
elevation of plasma CRP in patients with the coro-
nary artery disease. The fi ndings of Nagaoka (30) 
suggested that detrimental eff ects of CRP could 
also aff ect the ocular circulation and might partial-
ly contribute to development of the retinal vascu-
lar disease.
It has been demonstrated that CRP, in concentra-
tion known to predict vascular disease, directly in-
hibits the endothelium-dependent NO-mediated 
dilation of the isolated porcine retinal arterioles. 
The mechanism underlying the acute eff ect of CRP 
involves the activation of p38 kinase and the pro-
duction of superoxide by vascular NAD(P)H oxi-
dase. Recent clinical studies have demonstrated 
that statins are benefi cial by preserving the en-
dothelial function, possibly through the inactiva-
tion of the RhoA/Rho-kinase pathway and reduc-
tion of the oxidative stress. Since the impaired en-
dothelium-dependent NO-mediated dilation is a 
key feature of the early vascular events, it is clear 
that CRP is not only an infl ammatory marker but 
also a mediator of development of vascular disor-
ders in the retinal circulation. Reductions in infl am-
mation and oxidative stress or inhibition of RhoA/
Rho-kinase activity (for example by statins) have 
been reported to improve endothelial function 
(80,81).
It has been demonstrated that human CRP could 
be bound with highest affi  nity to phosphocholine 
residues, but it also binds to a variety of other au-
tologous and extrinsic ligands, and it aggregates 
or precipitates the cellular and molecular struc-
tures bearing these ligands. Autologous ligands 
include native and modifi ed plasma lipoproteins, 
damaged cell membranes, a number of diff erent 
phospholipids and related compounds, small nu-
clear ribonucleoprotein particles, and apoptotic 
cells. Binding of CRP to lipids, especially lecithin 
(phosphatidyl choline), and to plasma lipoproteins 
has been documented to be the fi rst step in gen-
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eration of foam cells and atherogenesis (82). It has 
been also demonstrated that aggregated, but not 
native, non-aggregated, CRP selectively binds only 
LDL and some VLDL particles from the whole se-
rum. Native CRP does bind to oxidized LDL and to 
partly degraded LDL, as found in atheromatous 
plaques (83). When aggregated or bound to mac-
romolecular ligands, human CRP is recognized by 
C1q and potently activates the classical comple-
ment pathway, engaging C3, the main adhesion 
molecule of the complement system, and the ter-
minal membrane attack complex, C5–C9. Bound 
CRP may also provide secondary binding sites for 
factor H and thereby regulate alternative-pathway 
amplifi cation and C5 convertases (84).
Conclusion
According to recent studies, CRP is defi nitely not 
only the infl ammatory marker but also a mediator 
for development of the vascular disorders in the 
retinal circulation. The results obtained from the 
present studies may help our understanding the 
pathogenesis of the retinal vascular disease associ-
ated with high levels of CRP. Since there is no cure 
for AMD, prevention is the fi rst approach to reduce 
vision loss. Control of modifi able risk factors such 
as smoking, hypertension, hyperlipoproteinemia, 
oxidative stress and chronic infl ammation could 
reduce the risk of developing AMD.
Vacabulary
The • choroid, also known as the choroidea or 
choroid coat, is the vascular layer of the eye, 
containing connective tissue, and lying be-
tween the retina and the sclera (85).
Retina•  is a light-sensitive tissue lining the inner 
surface of the eye. The optics of the eye create 
an image of the visual world on the retina, 
which serves much the same function as the 
fi lm in a camera (86).
The • pigmented layer of retina or retinal pig-
ment epithelium (RPE) is the pigmented cell lay-
er just outside the neurosensory retina that 
nourishes retinal visual cells, and is fi rmly at-
tached to the underlying choroid and overlying 
retinal visual cells (87).
The • fovea centralis, also generally known as 
the fovea, is a part of the eye, located in the 
center of the macula region of the retina. The 
fovea is responsible for sharp central vision (also 
called foveal vision), which is necessary in hu-
mans for reading, watching television or mov-
ies, driving, and any activity where visual detail 
is of primary importance (88).
The • macula or macula lutea (from Latin macula, 
“spot” + lutea, “yellow”) is an oval-shaped high-
ly pigmented yellow spot near the center of the 
retina of the human eye, and acts as a natural 
sunblock (analogous to sunglasses) for this area 
of the retina. The yellow colour comes from its 
content of lutein and zeaxanthin (89).
The • sclera (from the Greek skleros, meaning 
hard, also known as the white or white of the eye, 
is the opaque (usually white, though certain an-
imals, such as horses and lizards, can have black 
sclera), fi brous, protective, outer layer of the eye 
containing collagen and elastic fi ber (90).
Bruch’s membrane • is located between RPE 
and choroid and it represents a semipermeable 
fi ltration barrier through which major metabol-
ic exchange take place (91).
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Uloga CRP i upale u patogenezi makularne degeneracije povezane sa starošću
Sažetak
Makularna degeneracija povezana sa starošću (engl. age-related macular degeneration, AMD) kompleksna je, degenerativna i progresivna bolest 
koja uključuje višestruke genetske i okolišne čimbenike te može rezultirati ozbiljnim gubitkom vida. Etiologila AMD još se ne razumije u potpu-
nosti. Postoje mnoge teorije koje ističu mehanizme oksidativnog stresa, promjene nalik na aterosklerotske promjene, genetske predispozicije i 
upalu. Najnovija klinička istraživanja proučavaju važnu ulogu upale i C-reaktivnog proteina (CRP) u patogenezi AMD. Postoji veliki broj dokaza koji 
ukazuju na povezanost CRP-a s endotelnom disfunkcijom, oksidativnim stresom i stvaranjem reaktivnih kisikovih spojeva kao i s poremećajem 
lipidnog statusa kod bolesnika oboljelih od AMD. Prema navodima novijih istraživanja CRP defi nitivno nije samo upalni biljeg, već i posrednik u 
razvoju vaskularnih poremećaja u retinalnoj cirkulaciji. Rezultati dobiveni nedavno provedenim istraživanjima mogu pomoći pri razumijevanju 
patogeneze retinalne vaskularne bolesti povezane s visokom koncentracijom CRP-a.
Ključne riječi: makularna degeneracija povezane sa starošću; C-reaktivni protein; upala
